SGS Announces Results of H3N2 Influenza Trial

SGS announced the successful completion of a Phase I clinical trial of a new strain of influenza virus in healthy volunteers. The agent is approved for use as a challenge agent in studies demonstrating the early efficacy of influenza drugs and vaccines.

Read the full release here